 BioSig Technologies Inc has earned a reiterated Outperform rating and 4 price target from analysts at Noble Capital days after pricing a public offering that generated proceeds of 2.9 million. The offering was a bit unexpected, timing-wise, but supports PURE EP commercialization, the firm wrote. 